References
- HoyleMFuture drug prices and cost-effectiveness analysesPharmacoeconomics200826758960218563950
- ShihYCHanSCantorSBImpact of generic drug entry on cost-effectiveness analysisMed Decis Making2005251718015673583
- HayJWSmeedingJCarrollNVGood research practices for measuring drug costs in cost effectiveness analyses: issues and recommendations: the ISPOR Drug Cost Task Force report – Part IValue Health20101313719874571
- Guidelines for the Economic Evaluation of Health Technologies: Canada3rd EditionOttawaCanadian Agency for Drugs and Technologies in Health2006
- SorensenSVKansalARConnollySCost-effectiveness of dabigatran etexilate for the prevention of stroke and systemic embolism in atrial fibrillation: a Canadian payer perspectiveThromb Haemost2011105590891921431243
- Orange Book: Approved Drug Products with Therapeutic Equivalence Evaluations [webpage on the Internet]Silver Spring: US Food and Drug Administration Available from: http://www.accessdata.fda.gov/scripts/cder/ob/docs/patexclnew.cfm?Appl_No=022512&Product_No=001&table1=OB_RxAccessed October 2, 2014
- Register of Innovative Drugs [webpage on the Internet]OttawaHealth Canada [updated August 12, 2015]. Available from: http://www.hc-sc.gc.ca/dhp-mps/prodpharma/applic-demande/regist/reg_innov_dr-eng.phpAccessed July 8, 2015
- Guidance Document: Data Protection under C.08.004.1 of the Food and Drug Regulations [webpage on the Internet]OttawaHealth Canada2011 Available from: http://www.hc-sc.gc.ca/dhp-mps/prodpharma/applic-demande/guide-ld/data_donnees_protection-eng.phpAccessed July 8, 2015
- MoultonDProvincial squeeze on generic prices continuesCMAJ201118314E1049E105021896691
- BeallRFNickersonJWAttaranAPan-Canadian overpricing of medicines: a 6-country study of cost control for generic medicinesOpen Med201484e130e13525426181
- The Council of the FederationProvinces and Territories Seek Significant Cost Savings for Canadians on Generic Drugs 2013 Available from: http://www.councilofthefederation.ca/phocadownload/newsroom-2013/nr-cof-generic_drugs_final-jan_18.pdfAccessed May 10, 2014
- LawMRMoney left on the table: generic drug prices in CanadaHealthc Policy201383172523968624
- KongYCompetition between brand-name and generics – analysis on pricing of brand-name pharmaceuticalHealth Econ200918559160618816580
- BalabanDYDhallaIALawMRBellCMPrivate expenditures on brand name prescription drugs after generic entryAppl Health Econ Health Policy201311552352923979876
- LexchinJThe effect of generic competition on the price of brand-name drugsHealth Policy2004681475415033552
- BellCGrillerDLawsonJLovrenDGeneric Drug Pricing and Access in Canada: What are the Implications?TorontoHealth Council of Canada2010 Available from: http://www.healthcouncilcanada.ca/rpt_det.php?id=156Accessed May 10, 2014
- AcostaACiapponiAAaserudMPharmaceutical policies: effects of reference pricing, other pricing, and purchasing policiesCochrane Database Syst Rev201410CD00597925318966
- NarineLSenathirajahMSmithTEvaluating reference-based pricing: initial findings and prospectsCMAJ1999161328628810463052
- DylstPVultoASimoensSThe impact of reference-pricing systems in Europe: a literature review and case studiesExpert Rev Pharmacoecon Outcomes Res201111672973722098289
- KesselheimASMisonoASLeeJLClinical equivalence of generic and brand-name drugs used in cardiovascular disease: a systematic review and meta-analysisJAMA2008300212514252619050195
- BaumgärtelCMyths, questions, facts about generic drugs in the EUGaBI J2012113438
- DuerdenMGHughesDAGeneric and therapeutic substitutions in the UK: are they a good thing?Br J Clin Pharmacol201070333534120716231
- SimoensSBiosimilar medicines and cost-effectivenessClinicoecon Outcomes Res20113293621935330
- StewartAAubreyPBelseyJAddressing the health technology assessment of biosimilar pharmaceuticalsCurr Med Res Opin20102692119212620649394
- KesselheimASStedmanMRBubrickEJSeizure outcomes following the use of generic versus brand-name antiepileptic drugs: a systematic review and meta-analysisDrugs201070560562120329806
- MintzerSBrand spanking? The presumptive risks of generic anti-epileptic drugsEpilepsy Curr2011112545521852877